ARTICLE | Company News
Gilead, Southern Research Institute deal
January 2, 2001 8:00 AM UTC
GILD acquired an exclusive worldwide license from the institute to the nucleoside analog 4'-thio-araC (GS 7836), which is in preclinical development to treat cancer. GILD will be responsible for R&D c...